
NRSN Stock Forecast & Price Target
NRSN Analyst Ratings
Bulls say
NeuroSense Therapeutics has demonstrated significant progress with its Phase 2b PARADIGM study, achieving a statistically significant 29.2% reduction in disease progression for those treated with its lead product candidate, PrimeC. The company is also advancing its regulatory efforts to secure Canadian approval, with prospects for a 2026 launch, further enhancing its market position in neurodegenerative diseases. Furthermore, the favorable safety profile of PrimeC across its studies effectively de-risks the program, promising increased opportunities for strategic partnerships in North America and Europe that could provide non-dilutive capital for future growth.
Bears say
NeuroSense Therapeutics is facing a challenging financial situation, as its cash reserves are diminishing, indicating potential liquidity issues that could hinder ongoing operations and development. The anticipation of a necessary capital raise suggests that the company may struggle to fund its clinical initiatives and sustain growth without external financing. This financial strain, coupled with the inherent risks of clinical-stage biotechnology firms, contributes to a negative outlook for NeuroSense Therapeutics's stock.
This aggregate rating is based on analysts' research of NeuroSense Therapeutics Ltd and is not a guaranteed prediction by Public.com or investment advice.
NRSN Analyst Forecast & Price Prediction
Start investing in NRSN
Order type
Buy in
Order amount
Est. shares
0 shares